SynthesisEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Botulinum toxin for vocal fold granuloma: a systematic review and meta-analysis of treatment outcomes and recurrence.
Synthesis in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo synthesize outcomes after botulinum toxin A (BTX-A) injection for vocal process granuloma (VPG), including remission, recurrence, time to resolution, and safety.
methodsWe pooled 18 studies (n = 1,146 patients; 298 received BTX‑A) reporting clinical outcomes after BTX‑A injection for VPG. Random‑effects meta‑analysis produced pooled event rates with 95% confidence intervals; prespecified subgroup analyses compared primary versus refractory contact granulomas (CG) and intubation‑related granulomas (IG).
resultsOverall pooled complete remission after BTX‑A was 87.6% (95% CI 82.6-92.9%); most remissions occurred within 1-3 months. Subgroup pooled complete remission rates were 87.4% (95% CI 81.3-93.9%) for refractory CG, 91.1% (95% CI 79.8-103.9%) for primary CG, and 70.2% (95% CI 57.1-107.2%) for intubation‑related granulomas. Overall pooled Recurrence after initial remission was 6.9% (95% CI 3.1-15.5%); subgroup recurrence estimates were 9.4% for refractory CG, 5.7% for primary CG, and 19.8% for refractory IG. Pooled adverse‑event rates included hoarseness 9.1%, aspiration/choking 29.1%, and breathiness/dysphagia 29.4%; most events resolved within weeks to a few months. Objective voice‑quality measures were infrequently reported.
conclusionBTX‑A injection achieves high short-term remission and low Recurrence in VPG, with mostly transient side effects. It shows good durability in contact granulomas but less so in intubation-related lesions. More randomized studies with validated voice outcomes are needed to determine optimal dosing and long-term effectiveness.
Indexed as
Identifiers
42165887What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.